Moneycontrol PRO
Upcoming Webinar:Watch a panel of experts discuss: Challenges of continuously evolving regulation for Cryptocurrency, on 7th July at 3pm. Register Now

Buy Aarti Drugs; target of Rs 2090: Anand Rathi

Anand Rathi is bullish on Aarti Drugs has recommended buy rating on the stock with a target price of Rs 2090 in its research report dated July 28, 2020.

July 30, 2020 / 06:43 PM IST
  • bselive
  • nselive
Todays L/H

Anand Rathi 's research report on Aarti Drugs

As a prominent partner of pharma companies seeking to diversify supplies from China, Aarti’s Q1 sales grew 34% y/y. A better product mix and higher realisations on key APIs (prices rose 10-15%) led to a 772bp gross-margin expansion. The EBITDA margin swung to a record 24.6% (a 1,110bp expansion). Absolute EBITDA grew 145% to `1.3bn. The better operating performance and lower tax rate rocketed adj. PAT 281% to `855m. On such a strong Q1, we raise our FY21e/22e/23e EPS 43.5%/ 29.5%/28.9%. We expect revenue/PAT to clock 18.9%/34.5% CAGRs over FY20-23.


We retain our Buy rating, with a higher target of `2,090.


For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Jul 30, 2020 06:43 pm
ISO 27001 - BSI Assurance Mark